stockportfolio.pro
Stocks / ESPR vs KURA
ESPR vs KURA
Esperion Therapeutics, Inc. and Kura Oncology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Esperion Therapeutics, Inc. (ESPR) | Kura Oncology, Inc. (KURA) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $403.13M | $67.48M |
| Net income (latest FY) | $-22.68M | $-278.67M |
| Revenue growth (5y CAGR) | 12.1% | — |
| Net margin | -5.6% | -412.9% |
| Return on equity | 7.5% | -160.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ESPR — free Open KURA — freeFrequently asked questions
Which is bigger, ESPR or KURA?
Esperion Therapeutics, Inc. is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, ESPR or KURA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.